ArticleJournal of clinical immunology2013
MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1.
Article in Journal of clinical immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis.International journal of molecular medicine · 2017Pooled it
- Trial
- On the road to blood biomarkers in myasthenia gravis (MG): Beyond clinical scales.Journal of neuromuscular diseases · 2026Review
- From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia GravisEndocrine, metabolic & immune disorders drug targets · 2026Article
- Article
- Review
- The intricate dance of non-coding RNAs in myasthenia gravis pathogenesis and treatment.Frontiers in immunology · 2024Review
- Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis.Frontiers in molecular biosciences · 2024Review
- Circulating miRNAs drive personalized medicine based on subgroup classification in myasthenia gravis patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Review
- Article
- Exosomal miR-320e as a Novel Potential Biomarker for Cerebral Small Vessel Disease.International journal of general medicine · 2023Article
- Integrated Analysis and Identification of CSF-Derived Risk miRNAs and Pivotal Genes in Multiple Sclerosis.Journal of molecular neuroscience : MN · 2022Article
- Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis.BMC neurology · 2022Article
- Expression and Biological Functions of miRNAs in Chronic Pain: A Review on Human Studies.International journal of molecular sciences · 2022Review
- MicroRNA profiles in aqueous humor between pseudoexfoliation glaucoma and normal tension glaucoma patients in a Korean population.Scientific reports · 2022Article
- Article
- LncRNA LINC00680 Acts as a Competing Endogenous RNA and Is Associated With the Severity of Myasthennia Gravis.Frontiers in neurology · 2022Article
- A Review on the Role of Non-Coding RNAs in the Pathogenesis of Myasthenia Gravis.International journal of molecular sciences · 2021Review
- Identification of the regulatory role of lncRNA HCG18 in myasthenia gravis by integrated bioinformatics and experimental analyses.Journal of translational medicine · 2021Article
- Signaling pathways of genetic variants and miRNAs in the pathogenesis of myasthenia gravis.Gland surgery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) are T-cell dependent antibody-mediated autoimmune disorders, microRNAs are important regulators of human autoimmune disease pathogenesis. Here, we investigated the miRNAs expression profiles in MG for the first time and found that miR-320a was significantly downregulated in MG patients compared to normal healthy people. Meanwhile, pro-inflammatory cytokins in MG patients were overexpressed. Furthermore, we identified MAPK1 as a direct target of miR-320a. Downregulation of miR-320a induced the overexpression of pro-inflammatory cytokins through promoting COX-2 expression. This process was modulated by ERK/ NF-κB pathways. Taken together, our findings suggested that miR-320a could play a role in modulation of inflammatory cytokins production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.